| Filed On | Filing |
|---|---|
| 13 Nov 2026 | 10-Q |
| 13 Nov 2026 |
8-K: Results of Operations and Financial Condition
TAMPA, Fla., Nov. 13, 2026 -- TuHURA Biosciences, Inc. (NASDAQ:HURA) (“TuHURA” or the “Company”), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial re... |
| 06 Nov 2026 |
8-K: Creation of a Direct Financial Obligation
As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender. The Loan Agreement provides for a revolving credit facil... |
| 16 Oct 2026 |
8-K: Creation of a Direct Financial Obligation
As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender. The Loan Agreement provides for a revolving credit facil... |
| 24 Sep 2026 |
8-K: Creation of a Direct Financial Obligation
As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender. The Loan Agreement provides for a revolving credit facil... |
| 17 Sep 2026 |
8-K: Creation of a Direct Financial Obligation
As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender. The Loan Agreement provides for a revolving credit facil... |
| 17 Sep 2026 |
8-K/A: Departure/Election of Directors or Officers; Compensation
(a) Purpose. The TuHURA Biosciences, Inc. 2026 Inducement Equity Incentive Plan (the “Plan”) is intended to provide equity-based and cash incentive awards that qualify as employment inducement awards under the Nasdaq Rule. The Plan is in... |
| 16 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
(a) Purpose. The TuHURA Biosciences, Inc. 2026 Inducement Equity Incentive Plan (the “Plan”) is intended to provide equity-based and cash incentive awards that qualify as employment inducement awards under the Nasdaq Rule. The Plan is in... |
| 04 Sep 2026 |
8-K: Creation of a Direct Financial Obligation
As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender. The Loan Agreement provides for a revolving credit facil... |
| 28 Aug 2026 | SCHEDULE 13D/A |
| 21 Aug 2026 |
8-K: Creation of a Direct Financial Obligation
As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender. The Loan Agreement provides for a revolving credit facil... |
| 19 Aug 2026 |
8-K: Unregistered Sales of Equity Securities; Submission of Matters to a Vote of Security Holders
As previously disclosed in the Current Report on Form 8-K filed by TuHURA Biosciences, Inc. (the “Company”) with the Securities and Exchange Commission on April 22, 2026, on April 21, 2026, the Company entered into a Loan Agreement (the ... |
| 14 Aug 2026 | 10-Q |
| 14 Aug 2026 |
8-K: Results of Operations and Financial Condition
TAMPA, Fla., August 14, 2026 -- TuHURA Biosciences, Inc. (NASDAQ:HURA) (“TuHURA” or the “Company”), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial ... |
| 13 Aug 2026 |
8-K: Creation of a Direct Financial Obligation
As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender. The Loan Agreement provides for a revolving credit facil... |
| 29 Jul 2026 |
8-K: Creation of a Direct Financial Obligation
As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender. The Loan Agreement provides for a revolving credit facil... |
| 09 Jul 2026 | ARS |
| 09 Jul 2026 | DEFA14A |
| 09 Jul 2026 |
Proxy statement: annual meeting on August 18, 2026
CEO pay $4.0M, down 34% · say-on-pay vote |
| 07 Jul 2026 |
8-K: Creation of a Direct Financial Obligation
As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender. The Loan Agreement provides for a revolving credit facil... |
Loading...